Company profile
Viridian Therapeutics, Inc.
NASDAQ: VRDN · Healthcare · Biotechnology
#389 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
66BFH 50DQ 87GM 66SS 72
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ growth stability, Piotroski F
Methodology →Revenue TTM
$70.9M
Rev growth YoY (TTM)
+23382.8%
Net income (FY)
-$342.6M
Employees
252
as of 2026-08-09
Market cap
$2.1B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$70.8M$70.8M2025
Net income-$342.6M-$342.6M2025
Operating income-$363.4M-$363.4M2025
Total assets$899.4M$899.4M2025
Liabilities$177.3M$177.3M2025
Equity$722.2M$722.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License99%
Collaboration1%
By geography
Not disclosed.
The read
What is Viridian Therapeutics, Inc.’s revenue?
Viridian Therapeutics, Inc. booked $70.8M in FY2025 revenue, growing 23360% year over year — faster than 100% of Healthcare companies we track, at a -483.6% net margin.
Peers · Healthcare
Assembly Biosciences, Inc.63CCue Health Inc.——Avita Medical Inc.50DCodexis, Inc.61CBlack Diamond Therapeutics, Inc.60CPersonalis, Inc.59CNeighbors
Middlesex →Key facts
CEOStephen F. Mahoney
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: VRDN
Employees252
IPO date2014-06-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.